Earn CME: https://naccme.com/program/7311
In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Gail J. Roboz discusses minimal residual disease in acute myeloid leukemia (AML).
© 2018 Imedex, an HMP Company